Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Zoledronic Acid (Zometa) Clear all

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Thalidomide, zoledronic acid; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 4
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more

Conditions: Osteoporosis
Interventions: DMAB Discontinuation and Switching; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoporosis
Interventions: Zoledronic Acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 85 Years · Male only
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 16
States / cities: Tucson, Arizona • Walnut Creek, California • Lakewood, Colorado + 13 more

Conditions: Multiple Myeloma
Interventions: VELCADE, Lenalidomide, Dexamethasone, DVT prophylaxis, Bisphosphonates, Liposomal doxorubicin; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 2
States / cities: Memphis, Tennessee • Nashville, Tennessee

Conditions: Osteoporosis
Interventions: Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 80 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more

Conditions: Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Cancer
Interventions: Paclitaxel/Bev (control), Paclitaxel/Bev + ZA (experimental); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Zometa; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 56
States / cities: Birmingham, Alabama • Anchorage, Alaska • Anaheim, California + 50 more

Conditions: FHA (Functional Hypothalamic Amenorrhea)
Interventions: Romosozumab, Placebo, Zoledronic acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 30 Years · Female only
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Multiple Myeloma
Interventions: Zoledronic acid; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Interventions: zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 101
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Anaheim, California + 93 more

Conditions: IOP, Osteoporosis
Interventions: Alendronate, Zoledronic Acid; Drug
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 55 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Progeria
Interventions: Lonafarnib, Zoledronic Acid, and Pravastatin; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
Interventions: Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D; Drug · Dietary Supplement
Lead sponsor: Susan L. Greenspan; Other
Eligibility: 65 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Multiple Myeloma, Breast Cancer
Interventions: Zoledronic acid; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: West Hollywood, California • Greenwood Village, Colorado • Norwalk, Connecticut + 4 more

Conditions: Urologic Neoplasms
Interventions: zoledronic acid; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: letrozole, zoledronic acid; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteoporosis
Interventions: Zoledronic acid, Placebo, Teriparatide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 45 Years to 89 Years · Female only
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 18
States / cities: Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 15 more

Conditions: Osteopenia
Interventions: Zoledronic Acid, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Risk Factors for or a Diagnosis of Osteoporosis
Interventions: rHuPH20, zoledronic acid; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoporosis, Prostate Cancer
Interventions: cholecalciferol, calcium gluconate, zoledronic acid; Dietary Supplement · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Bone Loss, Prostate Cancer
Interventions: Zoledronic acid, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Disuse Osteoporosis
Interventions: Zoledronic acid; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Osteogenesis Imperfecta, Type I, Osteogenesis Imperfecta Type III, Osteogenesis Imperfecta Type IV
Interventions: setrusumab, Calcium, Vitamin D, zoledronic acid (optional); Drug · Dietary Supplement
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 12
States / cities: Birmingham, Alabama • Jacksonville, Florida • Baltimore, Maryland + 9 more

Conditions: Hormone-Refractory Prostate Cancer
Interventions: Zoledronic acid, Estramustine, Docetaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma

Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study

Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Romosozumab as an Adjunct to Physiologic Estrogen Replacement in Functional Hypothalamic Amenorrhea

Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates

Non-small Cell Lung Cancer Registry

Bisphosphonates for Prevention of Post-Denosumab Bone Loss

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

Romosozumab Use to Build Skeletal Integrity

Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer

Zoledronic Acid Administration in Acute Spinal Cord Injury

A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804

Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the Prostate